Holen Sie sich die Stockscreener-App
13.35
17.93%
2.03
Handel nachbörslich:
13.58
0.23
+1.72%
Schlusskurs vom Vortag:
$11.32
Offen:
$11.34
24-Stunden-Volumen:
3.62M
Relative Volume:
2.76
Marktkapitalisierung:
$618.70M
Einnahmen:
$217.11M
Nettoeinkommen (Verlust:
$-651.19M
KGV:
-1.0277
EPS:
-12.99
Netto-Cashflow:
$-387.26M
1W Leistung:
+41.57%
1M Leistung:
+55.78%
6M Leistung:
+3.49%
1J Leistung:
+16.66%
1-Tages-Spanne:
$11.28
$13.55
1-Wochen-Bereich:
$9.27
$13.55
52-Wochen-Spanne:
$5.00
$16.85
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Firmenname
Ginkgo Bioworks Holdings Inc
Sektor
Branche
Telefon
(877) 442-5362
Adresse
27 DRYDOCK AVENUE, BOSTON
Vergleichen Sie DNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
13.35 | 551.96M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-05-10 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-02 | Herabstufung | Goldman | Neutral → Sell |
| 2023-05-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-10-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-02-23 | Eingeleitet | Goldman | Neutral |
| 2022-02-01 | Eingeleitet | BofA Securities | Neutral |
| 2022-01-28 | Eingeleitet | BofA Securities | Buy |
| 2022-01-07 | Eingeleitet | BTIG Research | Buy |
| 2021-11-29 | Eingeleitet | Jefferies | Buy |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-10-12 | Eingeleitet | William Blair | Outperform |
| 2021-09-20 | Eingeleitet | HSBC Securities | Buy |
Alle ansehen
Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten
Is Ginkgo Bioworks Holdings Inc. a good long term investmentAccelerated profit realization - jammulinksnews.com
Ginkgo Bioworks Holdings Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
What analysts say about Ginkgo Bioworks Holdings Inc. stockHigh-octane gains - jammulinksnews.com
What drives Ginkgo Bioworks Holdings Inc. stock priceStrongest growth potential - jammulinksnews.com
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Sinks As Market Gains: Here's Why - MSN
Ginkgo Bioworks launches cost-effective ADME profiling service By Investing.com - Investing.com Canada
Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors - MarketScreener
Ginkgo Bioworks Holdings, Inc. (DNA) Outperforms Broader Market: What You Need to Know - sharewise.com
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Not Quite Adding Up - 富途牛牛
When the Price of (DNA) Talks, People Listen - news.stocktradersdaily.com
Ginkgo Bioworks Holdings (DNA) Shares Fall Despite Market Gains - AInvest
Ginkgo Bioworks (DNA) Shares Soar 5.29% on Q2 Earnings - AInvest
Ginkgo Bioworks (DNA) Soars 18.9%: Is Further Upside Left in the Stock? - MSN
Ginkgo Bioworks Surges 18.9%, Can Further Upside Be Expected? - AInvest
(DNA) On The My Stocks Page - news.stocktradersdaily.com
Ginkgo Bioworks Holdings, Inc.(NYSE: DNA) added to Russell 2500 Index - MarketScreener
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Moves 1.41%: What You Should Know - MSN
Ginkgo Bioworks: Is the Biotech's Undervalued Platform Poised for Scalable Growth? - AInvest
Ginkgo Bioworks stock rises on Hugging Face collaboration for AI drug development - Investing.com Canada
Lobbying Update: $10,000 of GINKGO BIOWORKS lobbying was just disclosed - Nasdaq
Ginkgo Bioworks Holds Annual Shareholder Meeting, Elects Directors - TipRanks
5 "Best" Publicly Traded Synthetic Biology Companies - Securities.io
Ginkgo Bioworks (DNA) Sees 5.4% Increase in Stock Price | DNA Stock News - GuruFocus
Where are the Opportunities in (DNA) - news.stocktradersdaily.com
Ginkgo Bioworks: Hedge Funds Pull Back and Other Important Updates - TradingView
Squarepoint Ops LLC Has $417,000 Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
From Promise to Peril: The Downfall of Ginkgo Bioworks - TradingView
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io
Northern Trust Corp Buys 9,791 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA) and Elanco Animal Health (ELAN) - The Globe and Mail
(DNA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Millennium Management LLC Has $6.58 Million Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care - Quantisnow
Ginkgo Bioworks: Cost-Cutting Efforts Aren't Enough (NYSE:DNA) - Seeking Alpha
Major Moves And Shakes In Health Care Sector - Finimize
Sector Update: Health Care - marketscreener.com
Finanzdaten der Ginkgo Bioworks Holdings Inc-Aktie (DNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):